Generalizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancer | Zendy

Misako Nagasaka | Zendy; Cliff Molife | Zendy; Zhanglin Lin Cui | Zendy; Victoria Jennifer Stefaniak | Zendy; Xiaohong Li | Zendy; Sangmi Kim | Zendy; Hsui-Yung Lee | Zendy; Julia Beyrer | Zendy; George R. Blumenschein | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Generalizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancer

Author(s) -

Misako Nagasaka,

Cliff Molife,

Zhanglin Lin Cui,

Victoria Jennifer Stefaniak,

Xiaohong Li,

Sangmi Kim,

Hsui-Yung Lee,

Julia Beyrer,

George R. Blumenschein

Publication year - 2022

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon-2022-0099

Subject(s) - medicine , lung cancer , population , oncology , pemetrexed , clinical trial , cohort , chemotherapy , environmental health , cisplatin

Aim: This retrospective study estimated efficacy and safety of sintilimab + pemetrexed + platinum (SPP) versus placebo + pemetrexed + platinum (PPP) in untreated locally advanced/metastatic, nonsquamous non-small-cell lung cancer (NSCLC), after adjusting each ORIENT-11 trial patient’s contribution to ORIENT-11 data based on characteristics of a target US population. Materials & methods: The target US population (n = 557) was selected from a real-world deidentified advanced NSCLC database based on key ORIENT-11 eligibility criteria. Inverse probability weights for ORIENT-11 patients (n = 397) relative to US patients were calculated. Efficacy and safety of SPP versus PPP were adjusted by inverse probability weights. Results: After adjustment, progression-free survival remained superior for SPP. Other efficacy and safety outcomes were consistent. Conclusion: These results provide evidence on how the effects observed with SPP in ORIENT-11 could translate to a US population with untreated locally advanced/metastatic nonsquamous NSCLC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research